After navigating a period of significant volatility, Trinity Biotech is demonstrating renewed strength through a series of strategic accomplishments. The biotechnology firm has successfully addressed critical compliance requirements while advancing its product pipeline, signaling a potential inflection point for the company's future trajectory. Regulatory and Market Position StrengthenedA primary concern for investors has been resolved as Trinity Biotech has regained full compliance with Nasdaq listing standards. Trinity Biotech has received regulatory clearance for outsourced manufacturing of its TrinScreen™ HIV rapid test, representing a strategic move toward cost optimization. AdFresh Trinity Biotech information released.